{'fraction_non_alphanumeric': 0.02093244529019981, 'fraction_numerical': 0.0009514747859181732, 'mean_word_length': 4.9772727272727275, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Research on Alzheimer's Disease: Time as a Factor in Anti-Herpes Drug Treating HSV1 Virus and A-ßeta Related Oligomer Plaques

Researches in the past had utilize anti-herpes medication on mice to determine its effect on treating Alzheimer’s Disease by eliminating possible plaque formations. While the medication was proved to be effective on mice, however, its usage on human patients in clinical trials indicated to have no results. Yet, patients in clinical trials are in terminal stages of the pathology, thus the effectiveness of any medication may be doubted. Based on this problem, this work designs a new experiment to assess the amplitude of the mice’s recovery from Alzheimer’s when they are injected with the Anti-herpes virus drug at different times. From comparing the extent of oligomer deposits to the experimental mice and the control group, we could obtain the best timing for the medication to be properly working. Then it can apply those on human Alzheimer’s patients at appropriate stage of the pathology for efficacious treatment.